Appraising the Role of PFO Closure

A review of updated trial data, available devices, and application of patent foramen ovale closure.

By Krishna S. Kallakuri, MD, and Rajeev L. Narayan, MD

Patent foramen ovale (PFO) is part of a group of entities known as atrial septal defects (ASDs), and it is a remnant of normal fetal anatomy. The PFO is a flap-like opening between the atrial septum secundum and primum at the fossa ovalis. In utero, it serves as a conduit for blood to the systemic circulation. Once the pulmonary circulation increases after birth, the functional PFO starts to close. Anatomic closure of the PFO usually occurs at about 12 months. However, in a certain population of people, the PFO will persist. A prospective study has shown that in the general population, the prevalence of PFO is as high as 25%, and data from 1988 show that the percentage is higher in young patients who have had a cryptogenic stroke, showing up to 40%. This has initiated tremendous interest and controversy over the years regarding the role that the PFO plays in cryptogenic stroke.

**MODALITIES TO DETECT PFO**

Transesophageal echocardiography (TEE) has been the gold standard for PFO detection. A meta-analysis of 164 patients that compared TEE with autopsy, cardiac surgery, and/or catheterization demonstrated a sensitivity of 89.2% and specificity of 91.4% to detect PFO. Another complementary and highly sensitive screening test is transcranial color Doppler (TCD) ultrasound. An investigation of 420 patients admitted for cryptogenic stroke, transient ischemic attack (TIA), or other neurologic symptoms, who underwent TCD and TEE evaluation, revealed that TCD had a sensitivity of 95% and a specificity of 92% in the diagnosis of PFO. It further concluded that TCD and TEE are complementary diagnostic tests for PFO, but TCD should be recommended as the first choice for screening because of its simplicity, noninvasive character, low cost, and high feasibility.

Another imaging modality is intracardiac echocardiography (ICE). A recent study with 65 patients compared the findings of TEE during the initial diagnostic examination with those from ICE acquired during the interventional procedure. It showed that ICE provided adequate views of the defects and surrounding structures during the various stages of device deployment, also finding additional anatomic variations in 12.3% of the patients. ICE is a safe and high-quality imaging technique for guiding transcatheter ASD and PFO occlusion and can be useful as a modality for diagnosis in cases in which TCD and TEE are indeterminate. As an adjunct to the procedure, ICE removes the requirement for general anesthesia that is required with TEE.

**PREVIOUS RESEARCH**

Multiple clinical trials have studied the role of PFO closure compared to medical therapy in patients with cryptogenic stroke or TIA. Earlier studies include CLOSURE I and the PC trial. Both concluded that the closure of PFO was not superior and did not offer a greater benefit than medical therapy alone in the prevention and recurrence of embolic events. Initial 1-year follow-up data from RESPECT demonstrated that in the intention-to-treat analysis, there was no significant benefit associated with the closure of a PFO in adults who had cryptogenic ischemic stroke. However, closure was superior to medical therapy alone in the prespecified per-protocol and as-treated analyses, with a low rate of associated risks. An analysis of CLOSURE I showed that there were independent risk factors and comorbidities that could have predicted recurrent ischemic neurologic events, suggesting an alternative etiology to paradoxical embolism was responsible for recurrent events. A meta-analysis of PC, RESPECT, and CLOSURE I intention-to-treat analyses showed a statistically significant risk reduction in stroke and/or TIA in the PFO closure group when compared to medical treatment and an even greater benefit in patients with a substantial shunt.

**RECENT RESEARCH**

More recent studies have shown a benefit toward PFO closure for cryptogenic stroke rather than medical
therapy alone (Figure 1), especially when the intervention is performed in select patients. CLOSE studied patients with a PFO and associated atrial septal aneurysm or large interatrial shunt and demonstrated that PFO closure combined with antiplatelet therapy lowered the rate of stroke recurrence greater than with antiplatelet therapy alone. An extended follow-up of the previous RESPECT trial showed that among adults who had a cryptogenic ischemic stroke, closure of a PFO was associated with a lower rate of recurrent ischemic strokes than medical therapy alone during the extended follow-up. Also, venous thromboembolism, which comprised events of pulmonary embolism and deep vein thrombosis, was more common in the PFO closure group, alluding to the fact that the closure prevented more potential recurrences of ischemic stroke.

The Gore REDUCE trial used the Helex septal occluder (Gore & Associates) or the Cardioform septal occluder (Gore & Associates) and found that among patients with a PFO who had a previous cryptogenic stroke, the risk of subsequent ischemic stroke was lower among those with PFO closure combined with antiplatelet therapy than those assigned to antiplatelet therapy alone. Although, the study did also find that PFO closure was associated with higher rates of device complications and atrial fibrillation. DEFENSE-PFO tried to determine which patients with cryptogenic stroke would be optimal candidates for closure. Researchers found that PFO closure in those with cryptogenic stroke and high-risk PFO characteristics (PFO with atrial septal aneurysm, hypermobility of atrial septum during Valsalva maneuver [phasic septal excursion into either atrium ≥ 10 mm], or PFO size [maximum separation of the septum primum from the secundum] ≥ 2 mm) resulted in a lower rate of a composite of stroke, vascular death, or thrombolysis in myocardial infarction—defined as major bleeding during 2 years of follow-up compared to the medication-only group.

Based on a patient-level meta-analysis of five randomized trials (CLOSURE I, PC, RESPECT, CLOSE, and Gore REDUCE), PFO-occluding devices decrease the risk of recurrent stroke compared with medical therapy in patients with cryptogenic stroke. Also, based on a subgroup analysis of the RESPECT trial, the efficacy of PFO closure for the prevention of stroke is enhanced in those patients with certain echocardiographic features, such as an atrial septal aneurysm or large shunt. Although there was a higher risk of atrial fibrillation found in patients who underwent PFO closure, based on these results, it can be concluded that in the right population of patients with high-risk PFO and cryptogenic stroke, PFO closure should be the standard of care.

Importantly, in these modern trials, an extensive evaluation prior to inclusion had been performed to exclude alternative causes of stroke. This included investigation with arrhythmia monitoring to exclude atrial arrhythmias, neurovascular imaging to exclude carotid artery disease, as well as extensive evaluation with stroke neurologists to ensure that patients had imaging-defined stroke/TIA that correlated with symptoms and had a high likelihood for embolic origin. Additionally, many of these trials were performed in patients between the ages of 18 and 60 years to exclude confounding variables that may contribute to stroke from nonparadoxical embolic origin. This has thus cemented the role of the heart-brain team to ensure appropriate patients are selected who would likely benefit from PFO closure.

**RISK STRATIFICATION**

The RoPE (risk of paradoxical embolism) index was created based on easily and reliably obtained variables that
may be useful to clinicians for predicting the probability of discovering a PFO in a patient with cryptogenic stroke. The index gives one point each for the following: no history of hypertension, no history of diabetes, no history of stroke or TIA, nonsmoker, and cortical infarct on imaging. Age is another factor, with the patient given five points if they are between 18 and 29 years of age, down to zero points if the patient is ≥ 70 years of age. A maximum score of 10 is possible with a minimum of 0. A score of 0 to 3 suggests a stroke is 0% to 4% attributable to PFO; however, a score of 9 to 10 makes a stroke 83% to 91% attributable to a PFO. The RoPE score estimated attributable fraction is highly correlated to the relative risk reduction of device versus medical therapy, and it identifies patients with cryptogenic stroke who are likely to have a PFO that is pathogenic rather than incidental.

COMMUNITY RESPONSE TO THE RESULTS

The American Academy of Neurology has updated its 2016 guidelines of PFO closure to reflect the new findings that were seen in recent studies (Table 1). This update in their guidelines shows the significant impact the recent trials have had and the shift toward PFO closure as a standard of care in cryptogenic stroke prevention, especially in optimized patients.

TABLE 1. MAJOR RECOMMENDATION UPDATES ON PFO CLOSURE FROM THE 2020 AMERICAN ACADEMY OF NEUROLOGY GUIDELINES

<table>
<thead>
<tr>
<th>Level B Recommendations</th>
<th>Level C Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>In patients being considered for PFO closure, clinicians should ensure that an appropriately thorough evaluation has been performed to rule out alternative mechanisms of stroke</td>
<td>In patients younger than 60 years with a PFO and embolic-appearing infarct and no other mechanism of stroke identified, clinicians may recommend closure after a discussion of potential benefits (absolute recurrent stroke risk reduction of 3.4% at 5 years) and risks (periprocedural complication rate of 3.9% and the increased absolute rate of nonperiprocedural atrial fibrillation of 0.33% per year)</td>
</tr>
<tr>
<td>In patients with a higher-risk alternative mechanism of stroke identified, clinicians should not routinely recommend PFO closure</td>
<td>In patients who opt to receive medical therapy alone without PFO closure, clinicians may recommend an antiplatelet medication such as aspirin or anticoagulation</td>
</tr>
<tr>
<td>Clinicians should counsel patients that having a PFO is common, that it occurs in about one in four adults in the general population, that it is difficult to determine with certainty whether their PFO caused their stroke, and that PFO closure probably reduces recurrent stroke risk in select patients</td>
<td>Abbreviations: PFO, patent foramen ovale.</td>
</tr>
</tbody>
</table>

PEARLS OF THE PROCEDURE

At our institution, evaluation of the patient with an embolic stroke of unknown source (ESUS) begins with extensive neurologic evaluation and imaging. Diagnostics may include transthoracic echocardiography, TCD, and TEE. Contemporaneous with the evaluation of PFO anatomy, low-risk patients for atrial arrhythmia undergo mobile telemetry monitoring for 1 month. Patients at higher risk for arrhythmia will undergo electrophysiologic consultation and implantable loop recorder monitoring to exclude atrial arrhythmia for 3 to 6 months. Additional neurovascular imaging to exclude carotid
### TABLE 2. PFO CLOSURE DEVICES AVAILABLE WORLDWIDE

<table>
<thead>
<tr>
<th>Device</th>
<th>Size (RA/LA disc mm)/ Sheath (F)</th>
<th>Features</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amplatzer PFO occluder (Abbott)</td>
<td>(18/18)/8 F (25/18)/8 F (35/25)/9 F</td>
<td>Unique design with durable nitinol wire mesh with polyester fabric thread to be seen well under fluoroscopy; asymmetric double-disc design minimizes material in LA; intaglio wire treatment to reduce nickel leaching; capability to be fully recaptured and fully repositioned. Pros: Device with the most data in literature and RCTs; good efficacy in all anatomies, especially in the case of rigid tunnels. Cons: Potential risk of erosion (especially larger devices, but no cases in RCTs); future transseptal access is possible but complex; thrombogenicity.</td>
</tr>
<tr>
<td>Cardioform septal occluder (Gore &amp; Associates)</td>
<td>(20/20)/10 F (25/25)/10 F (30/30)/10 F</td>
<td>Innovative minimal wall injury design features two independent, conformable discs to span and cover the anatomy, allowing for rapid endothelialization; it is a permanent implant consisting of a nitinol wire frame covered with a thin ePTFE membrane. Pros: Device is less rigid than Amplatzer, with a thinner profile and good conformability to different anatomies; coating of external ePTFE without exposing nitinol; low thrombogenicity and low risk of erosion; potentially easier to recross with new transseptal access than Amplatzer. Cons: Higher risk of atrial fibrillation than Amplatzer in RCTs; greater residual shunt in the REDUCE trial compared to other RCTs.</td>
</tr>
<tr>
<td>NobleStitch EL (HeartStitch)</td>
<td>1 size/12 F</td>
<td>NobleStitch EL used in combination with the KwikNots (HeartStitch) provides the simplest, most intuitive, least invasive solution to vascular and cardiovascular procedures by using a single stitch to close the opening between heart chambers. Pros: Closure of the PFO without a metal device; postimplantation antithrombotic therapy is not required; no risk of erosion; possibility of future transseptal puncture. Cons: Less applicable in difficult anatomies, and there is a learning curve; contrast medium and fluoroscopy dose potentially higher than other devices; poor clinical data.</td>
</tr>
<tr>
<td>CeraFlex PFO occluder (Lifetech Scientific)</td>
<td>(18/18)/9 F (25/18)/10 F (25/25)/10 F (30/25)/12 F (30/30)/12 F (35/25)/14 F</td>
<td>Unique ball connection between pusher and Occluder safely locks it, while it freely follows the anatomy, and once in place, it is easy to deliver; handknitted biocompatible PET-patch allows immediate verification of the occlusion effect by ultrasound and x-ray; titanium oxide–covered nitinol for best value biocompatibility; optimized braiding, no hub, and reduced material on LA disc guarantees better ingrowth. Pros: Nickel-free outer coating; articulated release system with device (less tension during implantation); no hub to the left, less traumatic, and potentially less thrombogenic. Cons: Much less extensive experience and literature than Amplatzer and Cardioform; future transseptal access is possible but complex; unknown erosion risk.</td>
</tr>
<tr>
<td>Hyperion PFOO-II (Comed)</td>
<td>(18/18)/10 F (24/18)/10 F (28/22)/12 F (34/25)/12 F</td>
<td>Dual articulating sails designed within the device allow for easy deployment and create an ideal super-low profile within the atria; an integral locking delivery and retrieval mechanism ensures safe and stable positioning of the Ultrasent device within the foramen ovale; devices are fully retrievable both before and after release.</td>
</tr>
<tr>
<td>Ultrasent PFO occluder (Cardia Inc.)</td>
<td>(20/20)/10 F (25/25)/10 F (30/30)/11 F (35/35)/11 F</td>
<td>Due to the single-wire design, there is no need for protruding clamps, resulting in an exceptionally low profile; the occluder consists of a double-layer right atrial disc and a single-layer left atrial disc; the thromboembolic risk is lowered by reducing the amount of nitinol being used in the LA (50%); PET, a synthetic material, is incorporated in the right atrial double disc to achieve a high acute closure rate; the left atrial disc is a single disc to accelerate the endothelialization process.</td>
</tr>
<tr>
<td>Nit-Occlud PFO (PFM Medical)</td>
<td>(20/20)/9 F (26/26)/9 F (30/30)/10 F</td>
<td>72 preoxidized nitinol wires with symmetrical and asymmetrical disc design, with or without hub design.</td>
</tr>
</tbody>
</table>
vascular disease and adjunctive hematology evaluation for hypercoagulable disorders are performed.

Procedurally, we generally propose that PFO closure can be safely performed using ICE and fluoroscopy. Using a multipurpose or Judkins right diagnostic catheter and soft tip straight guidewire (such as the Magic Torque guidewire, Boston Scientific Corporation), clockwise rotation of the catheter while engaging the septum is often sufficient to cross the PFO. The catheter is advanced through the PFO and into the left atrium and the wire is then advanced through the catheter and into the left superior pulmonary vein. Following this, either the Amplatzer or Gore delivery system is advanced over the wire, and the selected device is deployed as per the instructions for use.

On occasion, due to restrictive tunnel or serpiginous defect, crossing can become challenging. In these instances, a transseptal approach can be helpful. Using a radiofrequency puncture system (Baylis Medical Company, Inc.), peri-PFO puncture can be performed, allowing for device deployment and successful PFO closure. This latter approach requires a strong knowledge of transseptal puncture and device delivery and should only be attempted by operators with significant experience.

**FUTURE DEVICES**

There have been multiple devices on the horizon for PFO closure, one of which is the BioStar bioabsorbable septal repair implant (Gore & Associates). This device showed successful implantation in 98% of patients, with successful closure in 92% at 30 days and 96% in 6 months. BioStar is a novel septal repair implant because it can cause biologic closure of atrial-level defects using a patient’s natural healing response, allowing for 90% to 95% of the implant to be absorbed and replaced with healthy native tissue. Another device, the Carag bioresorbable septal occluder (Carag AG), has also shown promise as a bioresorbable implant for PFO closure that could reduce possible long-term complications. It has demonstrated good biocompatibility with documentation of timely degradation and substitution of the polymer material by fibromuscular cells and extracellular matrix components in animal models. Additionally, the Figulla Flex II (Occlutech International AB) has been shown to have a 100% implantation success rate in a study done with 82 patients and no major complications or recurrences of cerebral thromboembolic events in 6 months. A difference with this device compared to others is a unique braiding technique in forming a single hub (microscrew) at the right atrial disc for cable connection. Consequently, there is no left atrial clamp, minimizing the amount of material implanted. This may contribute to this device’s low complication rate but a relatively high percentage of small residual shunts 6 months after closure. Currently the device is in use in Europe but not in the United States as it is not FDA approved. Another novel approach to PFO closure is the NobleStitch EL (HeartStitch), which is a suture-mediated “deviceless” closure of the PFO. This system is feasible in the majority of septal anatomies, providing an effective closure of PFO comparable to traditional devices, with a good safety profile in a medium-term follow-up. NobleStitch EL is being evaluated in an ongoing clinical trial called STITCH (NCT04339699) that is comparing it to the Amplatzer PFO occluder to prevent recurrent ischemic stroke.
OTHER ASSOCIATIONS WITH PFO

PFO has been associated with many different conditions. In 2004, a study with 230 scuba divers, of whom 63 had a PFO, showed that the presence of a PFO is related to a low absolute risk of five major decompensation illness (DCI) events per 10,000 dives, the odds of which are five times as high as in divers without PFO. Additionally, the study found that the risk of developing a major DCI parallels PFO size.28

Another association has been made between PFO and migraines. A prospective analysis of 110 patients with PFO and ASD that were closed showed that 49% also experienced migraines. Of those who also had migraines, 82% of the PFO patients and 89% of the ASD patients showed that the percutaneous closure offered migraine relief.29 There is still controversy on the subject because other randomized controlled trials, such as PREMIUM and PRIMA, did not show that PFO closures were superior for migraine reduction.30,31 However, there may be a role for PFO closure according to a recent retrospective study that showed that patients who had a complete closure or also had an aura with migraines were more likely to improve with intervention.32

The third association with PFO is platypnea-orthodeoxia syndrome, a rare condition characterized by hypoxia in the upright position that is improved in the supine position. Of the patients who had platypnea-orthodeoxia, 64.8% were classified as having “improved SaO2”; they experienced improvement or complete resolution of their dyspnea and hypoxemia after PFO closure. Patients with no change after PFO closure predominantly had a pulmonary etiology for their hypoxia, showing that PFO closure may resolve symptomatic postural dyspnea and hypoxemia and is an effective treatment for platypnea-orthodeoxia, but it is not as effective if the primary etiology of the hypoxemia is due to a pulmonary cause.33

These various studies show that PFO closure should not just be limited to cryptogenic stroke; there is a multitude of other variables when considering the percutaneous closure of a PFO.

CONCLUSION

PFO closure has evolved over the past several decades and now occupies a role as a standard of care for patients with ESUS/cryptogenic stroke. Future directions include the development of novel PFO closure devices along with expansion to treat alternative conditions possibly related to the PFO.